Guanylin and uroguanylin are peptides that bind to and activate guanylate cyclase C and control salt and water transport in many epithelia in vertebrates, mimicking the action of several heat-stable bacteria enterotoxins. In the kidney, both of them have well-documented natriuretic and kaliuretic effects. Since atrial natriuretic peptide (ANP) also has a natriuretic effect mediated by cGMP, experiments were designed in the isolated perfused rat kidney to identify possible synergisms between ANP, guanylin and uroguanylin. Inulin was added to the perfusate and glomerular filtration rate (GFR) was determined at 10-min intervals. Sodium was also determined. Electrolyte dynamics were measured by the clearance formula. Guanylin (0.5 µg/ml, N = 12) or uroguanylin (0.5 µg/ml, N = 9) was added to the system after 30 min of perfusion with ANP (0.1 ng/ml). The data were compared at 30-min intervals to a control (N = 12) perfused with modified Krebs-Hanseleit solution and to experiments using guanylin and uroguanylin at the same dose (0.5 µg/ml). After previous introduction of ANP in the system, guanylin promoted a reduction in fractional sodium transport (%TNa + , P<0.05) (from 78.46 ± 0.86 to 64.62 ± 1.92, 120 min). In contrast, ANP blocked uroguanylin-induced increase in urine flow (from 0.21 ± 0.01 to 0.15 ± 0.007 ml g -1 min -1 , 120 min, P<0.05) and the reduction in fractional sodium transport (from 72.04 ± 0.86 to 85.19 ± 1.48, %TNa + , at 120 min of perfusion, P<0.05). Thus, the synergism between ANP + guanylin and the antagonism between ANP + uroguanylin indicate the existence of different subtypes of receptors mediating the renal actions of guanylins. 
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C) and causes chloride secretion in the T84 colon cancer cell line (2) .
Uroguanylin is another analog of STa that was first isolated from rat urine and increases the levels of cGMP in T84 cells and also causes chloride secretion in enterocytes via cystic fibrosis conductance membrane regulator (3, 4) . Uroguanylin is expressed in the heart, kidney and intestine (5) . STa is more potent than uroguanylin, which in turn is more potent than guanylin in the induction of cGMP accumulation in T84 cells (5) . Uroguanylin may have a pivotal role in a novel endocrine axis involving the gut, the heart and the kidney. The intestine may be able to detect the amount of salt ingested and match this load to the excretion of salt by the kidney (4, 6) .
Both guanylin and uroguanylin have kaliuretic and natriuretic effects in the isolated kidney, similar to those observed for STa (6, 7) . The actions of cGMP in the kidney were previously demonstrated by Lima and coworkers (7) . Also in the kidney uroguanylin has been shown to be more potent than guanylin. Previous work from this laboratory demonstrated that lysilguanylin is also natriuretic (8) .
Atrial natriuretic peptide (ANP) is a 28-amino acid peptide with well-known effects in the regulation of salt and water excretion in the kidney. It also plays a role in the regulation of arterial blood pressure in a saltsensitive fashion, interacting with other hormonal systems such as the renin-angiotensinaldosterone system (9, 10) . ANP binds to and activates guanylate-cyclase A in the kidney (11) .
Since the actions of guanylins and ANP are mediated by cGMP, and the three peptides share many similar functions in the kidney, experiments were designed to determine a possible synergism between guanylins and ANP in the isolated rat kidney.
Wistar rats weighing 250-300 g with free access to water were fasted for 24 h and anesthetized with sodium pentobarbital (50 mg/kg, ip). The right kidney was perfused with a modified Krebs-Hanseleit solution as control (Cont, N = 12), according to the technique previously described by Fonteles et al. (12) . At 10-min intervals samples of both urine and perfusate were obtained and analyzed for inulin by the method previously described by Wasler (13) and modified by Fonteles (12) and electrolytes were determined by flame photometry. Glomerular filtration rate (GFR), fractional tubular transport of sodium (%TNa + ), as well as urine flow (UF), osmotic clearance (Cosm) and perfusion pressure were also determined at 10-min intervals, using the clearance method as previously described (14) . A sylastic oxigenator was placed in the perfusion line for oxygenation of the perfusates (pO 2 = 450-500 mmHg) according to Fonteles et al. (12) . Rat guanylin and opossum uroguanylin were synthesized by a solid-phase method (15) . The structure and purity of the peptides were confirmed by amino acid analysis, electrospray mass spectrometry and gas phase sequence analysis. The ANP used in these experiments was purchased from Sigma Chemical Co., St. Louis, MO, USA.
After 30 min of perfusion with ANP (0.1 ng/ml), guanylin (0.5 µg/ml, N = 12) or uroguanylin (0.5 µg/ml, N = 9) was added to the system and the data (reported as means ± SEM) were obtained by comparing the results at 30-min intervals to the internal control and to experiments in which the kidney was perfused only with uroguanylin or guanylin at the same dose (0.5 µg/ml). The doses of guanylin and uroguanylin employed in this study were based on previous reports by Fonteles and coworkers (16) that established a dose-response curve of guanylin and uroguanylin in the perfused rat kidney assay. Statistical analysis was carried out by the Fisher test (based on one-way ANOVA), and with the level of significance set at P<0.05.
Pretreatment with ANP clearly promoted natriuresis, reflected as a reduction in %TNa + (Figure 1, panel A) and also caused an increase in diuresis (urinary flow; Figure 1 , panel B) in guanylin-treated kidneys. ANP also increased Cosm (from 0.08 ± 0.01 to 0.412 ± 0.071 ml g -1 min -1 , 120 min, P<0.05) in guanylin-treated kidneys. In contrast to these observations, ANP blocked the uroguanylin-induced natriuresis and increase in UF, as shown in Table 1 . ANP also blocked the uroguanylin-induced increase in Cosm (from 0.20 ± 0.01 to 0.087 ± 0.004 ml g -1 min -1 , 120 min, P<0.05).
The results of Cosm promoted by pretreatment with ANP in both guanylin and uroguanylin-treated kidneys suggest that the interactions between the peptides occur at a nephron site away from distal tubules, since vasopressin was not added to the system at any time.
We should emphasize that neither ANP nor guanylin has any natriuretic effect at this dose (Figure 1 ). At these doses neither uroguanylin or guanylin caused any significant changes in perfusion pressure or in glomerular filtration rate, and ANP did not change this pattern (data not shown).
Thus the synergism between ANP + guanylin and the unexpected antagonism between ANP + uroguanylin suggest the existence of new receptors or new isoforms of GC-C mediating the renal actions of guanylins. Until now, there are no other receptors known to mediate any action of guanylins or STa, but other ligand sites have been recognized (17) . GC-C has two kinetically distinct states with different affinity for 125 I-labeled STa (18) . Cross-talking between the guanylin/STa receptor and ANP receptor at the level of intracellular signal transduction is another explanation for these observations, since they share amino acid homology.
There are different mediators that regulate kidney salt and water excretion that may involve potential interactions between guanylin and uroguanylin, such as FNS (factor natriureticus similis), a peptide liberated from the hypoxic perfused rat kidney that causes natriuresis through an increase in cGMP (19) , and urodilatin, another natriuretic peptide that increases the level of cGMP within renal cells (20) .
If our initial observation is confirmed after the survey of other interactions between guanylin, uroguanylin and the other mediators mentioned above, new experiments should be done in order to search for these new subtypes of receptors, using cDNA cloning and immunocytochemistry. Studies with guanylin/uroguanylin antagonists provide another good perspective for the future, since these compounds are not available at this time.
